• 1
    O'Brien ET, Murphy J, Tyndall A, et al. Twenty-four-hour ambulatory blood pressure in men and women aged 17 to 80 years: the Allied Irish Bank Study. J Hypertens. 1991;9:355360.
  • 2
    Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension: systolic hypertension in Europe trial investigators. JAMA. 1999;282:539546.
  • 3
    Krause T, Lovibond K, Caulfield M, et al; Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.
  • 4
    Verdecchia P, Schillaci G, Porcellati C. Dippers versus non-dippers. J Hypertens. 1991;9:4248.
  • 5
    Higashi Y, Nakagawa K, Kimura M, et al. Circadian variation of blood pressure and endothelial function in patients with essential hypertension: a comparison of dippers and non-dippers. J Am Coll Cardiol. 2002;40:239243.
  • 6
    Syrseloudis D, Tsioufis C, Aragiannis D, et al. The dominant role of the systolic component of nondipping status on target-organ damage in never-treated hypertensives. Am J Hypertens. 2011;24:292298.
  • 7
    Cicek Y, Durakoglugil ME, Kocaman SA, et al. Non-dipping pattern in untreated hypertensive patients is related to increased pulse wave velocity independent of raised nocturnal blood pressure. Blood Press. 2013;22:3438.
  • 8
    Erden M, Kocaman SA, Poyraz F, et al. Incremental effects of serum uric acid levels, autonomic dysfunction, and low-grade inflammation on nocturnal blood pressure in untreated hypertensive patients and normotensive individuals. Turk Kardiyol Dern Ars. 2011;39:531539.
  • 9
    Gür M, Elbasan Z, Şahin DY, et al. DNA damage and oxidative status in newly diagnosed, untreated, dipper and non-dipper hypertensive patients. Hypertens Res. 2013;36:166171.
  • 10
    Ohkubo T, Imai Y, Tsuji I, et al. Relation between nocturnal decline in blood pressure and mortality, the Ohasama Study. Am J Hypertens. 1997;10:12011207.
  • 11
    Sato Y, Yamamoto E, Sawa T, et al. High-sensitivity cardiac troponin T in essential hypertension. J Cardiol. 2011;58:226231.
  • 12
    de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:25032512.
  • 13
    Hellemons ME, Lambers Heerspink HJ, Gansevoort RT, et al. High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case–control study with confirmation in diabetes. J Hypertens. 2013;31:805812.
  • 14
    Stergiou GS, Salgami EV; World Health Organization-International Society of Hypertension (WHO-ISH), USA Joint National Committee on Prevention, Detection, Evalutiaon, Treatment of High Blood Pressure (JNC-7), European Society of Hypertension-European Society of Cardiology (ESH-ESC). New European, American and International guidelines for hypertension management: agreement and disagreement. Expert Rev Cardiovasc Ther. 2004;2:359368.
  • 15
    Hoshide S, Fukutomi M, Eguchi K, et al. clinical and change in high-sensitive cardiac troponin T on hypertensive treatment. Clin Exp Hypertens. 2013;35:4044.
  • 16
    Lang RM, Bierig M, Devereux RB, et al; Chamber Quantification Writing Group. Recommendations for Chamber Quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:14401463.
  • 17
    Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358367.
  • 18
    Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man, anatomic validation of the method. Circulation. 1977;55:613618.
  • 19
    Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302:4957.
  • 20
    Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356:830840.
  • 21
    Hickman PE, Potter JM, Aroney C, et al. Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chim Acta. 2010;411:318323.
  • 22
    Fortu˜no MA, Ravassa S, Fortu˜no A, et al. Cardiomyocyte apoptotic cell death in arterial hypertension: mechanisms and potential management. Hypertension. 2001;38:1406.
  • 23
    Dogan SM, Aydin M, Gursurer M, et al. N-terminal probrain natriuretic peptide predicts altered circadian variation in essential hypertension. Coron Artery Dis. 2007;18:347352.
  • 24
    Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321328.
  • 25
    Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis. 2002;44:293321.
  • 26
    Rubin J, Matsushita K, Ballantyne CM, et al. Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol. 2012;59:484489.
  • 27
    Yiu KH, Zhao CT, Chen Y, et al. Association of subclinical myocardial injury with arterial stiffness in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12:94.